Anadys picks ANA 773 for next clinical program

New York, Dec. 13 - Anadys Pharmaceuticals, Inc. said it has chosen ANA773, a novel toll-like receptor-7 (TLR-7) oral prodrug, for its next clinical development program.

ANA773 is being developed as an oral therapy for the treatment of certain cancers. The drug is wholly owned by Anadys.

"Agonists of TLR-7 have significant potential for treating a variety of diseases," said Steve Worland, Anadys' executive vice president for research and development, in a news release.

"We believe ANA773 may be effective in certain types of cancer."

The San Diego-based biopharmaceutical company expects to begin phase 1 clinical trials in the second half of 2006.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.